Cancer modeling in the modern era: Progress and challenges

Cell

Volumn 108, Issue 2, 2002, Pages 135-144

  Van Dyke, Terry ^a   Jacks, Tyler ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CANCER MODEL; CANCER RESEARCH; CELL SPECIFICITY; GENE MUTATION; GENETIC ENGINEERING; GERM LINE; IMAGING; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 0037169361     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)00621-9     Document Type: Review

References (88)

1. Transgenic models of tumor development
2. Use of transgenic mice in identifying chemopreventive agents
3. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
4. The role of p53 in tumour suppression: Lessons from mouse models
5. Cancer as a complex genetic trait: Tumor susceptibility in humans and mouse models
6. Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances
7. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
8. Imaging brain structure and function, infection and gene expression in the body using light
9. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
10. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis
11. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
12. Turning on tumors to study cancer progression
13. Cancer. Improved mouse models
14. Building 'validated' mouse models of human cancer
15. Molecular mechanisms of tumor angiogenesis and tumor progression
16. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling
17. Essential role for oncogenic Ras in tumour maintenance
18. Mouse models of tumor development in neurofibromatosis type 1
19. Manipulating the germline: Its impact on the study of carcinogenesis
20. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
21. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo
22. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice
23. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
24. Time-sensitive of hyperplasia in transgenic mice expressing SV40 T antigen
25. Reversible tumorigenesis by MYC in hematopoietic lineages
26. Development of a flexible and specific gene delivery system for production of murine tumor models
27. Induction and apoptotic regression of lung adenocarcinomas by regulation of K-Ras transgene in the presence and absence of tumore suppressor genes
28. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography
29. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2
30. Expression profiling and identification of novel genes in hepatocellular carcinomas
31. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice
32. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
33. Seeing is believing: Non-invasive, quantitative and repetitive imaging of reporter gene expression in living animals, using positron emission tomography
34. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas
35. Visualization of GFP-expressing tumors and metastasis in vivo
36. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
37. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice
38. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
39. Tumor suppressor gene mutations in mice
40. Analysis of lung tumor initiation and progression using conditional expression of oncogenis K-ras
41. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
42. Apoptosis: A link between cancer genetics and chemotherapy
43. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
44. High resolution computed tomography and MRI for monitoring lung tumor growth in mice undergoing radioimmunotherapy: Correlation with histology
45. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
46. Transgenic mouse models for tumour-suppressor genes
47. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
48. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
49. Leukaemia disease genes: Large-scale cloning and pathway predictions
50. Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction
51. Multicolour spectral karyotyping of mouse chromosomes
52. Mouse models dissect the role of p53 in cancer and development
53. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability
54. Cancer predisposition caused by elevated mitotic recombination in Bloom mice
55. Insights into cancer from transgenic mouse models
56. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells
57. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum
58. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors
59. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene
60. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
61. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
62. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: Protein transferase inhibitor
63. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system
64. A key role for E2F1 in p53-dependent apoptosis and cell division within developing tumors
65. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma
66. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion
67. A causal role for E-cadherin in the transition from adenoma to carcinoma
68. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
69. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
70. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
71. Unraveling human cancer in the mouse: Recent refinements to modeling and analysis
72. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
73. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
74. In vivo evaluation of 5-[(18)F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model
75. DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice
76. Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice
77. Visualizing the kinetics of tumor-cell clearance in living animals
78. p53-dependent apoptosis suppresses tumor growth and progression in vivo
79. Conditional expression of fibroblast growth factor-7 in the developing and mature lung
80. Primary subtype C HIV-1 infection in Harare
81. ARF is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo
82. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter
83. Cancer susceptibility and the functions of BRCA1 and BRCA2
84. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis
85. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation
86. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
87. Specific protection against breast cancers by cyclin D1 ablation
88. Rapid in vivo functional analysis of transgenes in mice using whole body imaging of luciferase expression